Health & Biotech
Exopharm (ASX:EX1) is a leader in advancing Genetic Medicines and other exosome-based medicines using exosomes or extracellular vesicles (EVs) as a chassis for improved and non-viral drug-delivery.
Exopharm (ASX:EX1) is pursuing a product pipeline-driven platform strategy. Exosomes can be loaded with a variety of active pharmaceutical ingredients (APIs) and can be targeted to selected cell-types and tissue types, improving the safety-profile of the APIs and providing better treatments. Exosomes can be used to deliver small molecule drugs, mRNA, DNA and other types of APIs.
Exosomes are an alternative means of drug-delivery inside the body, alongside technologies such as lipid nanoparticles (LNP), cell-penetrating peptides, viral vectors and liposomes.
Exopharm’s exosome technologies solve important needs for the success of exosome medicines – LEAP manufacturing technology, LOAD API loading technologies and EVPS tropism technologies.
Exosome-based medicines could improve the treatment of many chronic or inherited medical conditions.
Exopharm is making its proprietary technologies available to pharmaceutical and biotechnology companies that want to harness exosome-delivery for their own products.
In addition, Exopharm is using its technology platform to enable its own product development programs – each aimed at delivering a transformative medicine for an unmet medical need.
KEY PEOPLE
RELATED STOCKHEAD STORIES
Health & Biotech
Exopharm and Astellas team up for exosomes evaluation
Health & Biotech
Exopharm secures US patent for exosomes purification technology
Health & Biotech
ASX Health Stocks: Lumos is ready to seek regulatory approval for its COVID-19 rapid antigen test
News
Market Highlights and 5 ASX Small Caps to watch on Wednesday
Health & Biotech
Exopharm shares soar 12pc on Q1 update as LEAP tech promises to advance wide range of medicines
Health & Biotech
Exopharm appoints two key executives as it transitions into a global exosomes company
Health & Biotech
Exopharm signs deal with Japanese chemical company as LEAP tech promise to accelerate new cancer-beating research
News
ASX Health Stocks: Medical imaging player Resonance Health leads the pack with FY21 revenue increase
Stockhead TV
V-Con: Talking medical innovations and breakthrough treatments with ASX biotechs
Health & Biotech
Exopharm takes major step forward in global strategy with approval for its first national patent
Health & Biotech
$12m capital raising puts Exopharm in strong position to negotiate new partnerships
Health & Biotech
Pitt Street Research says Exopharm worth up to $4.71 a share
Health & Biotech
Exopharm’s great LEAP forward gets an all-clear cheers from Finland’s Red Cross service
News
Market highlights and 5 ASX small caps to watch on Tuesday
News
Closing Bell: Today’s biggest small cap movers on the ASX
Health & Biotech
Bard1 caps off 600pc+ in 6 weeks proving it can detect another type of cancer
Health & Biotech